Literature DB >> 18463045

Preoperative tumor localization by means of venous sampling for fibroblast growth factor-23 in a patient with tumor-induced osteomalacia.

Per-Anton Westerberg1, Hannes Olauson, Göran Toss, Björn Wikström, Ollallo Morales, Torbjörn Linde, Kenneth Jonsson, Osten Ljunggren, Tobias E Larsson.   

Abstract

OBJECTIVE: To report on a novel strategy for tumor localization in a 62-year-old man with hypophosphatemic tumor-induced osteomalacia (TIO).
METHODS: Repeated computed tomographic and magnetic resonance imaging scans failed to localize any tumor in a patient with adult-onset hypophosphatemic osteomalacia. Therefore, venous sampling for fibroblast growth factor-23 (FGF23)--a circulating hormone that has been identified as a causative factor for TIO--in major veins was conducted. Serum FGF23 was measured from collected samples by an intact FGF23 enzyme-linked immunosorbent assay.
RESULTS: Venous sampling suggested a local increase in serum FGF23 in the left femoral vein; this finding prompted performance of octreotide scintigraphy restricted to the left leg. A tumor was located at the lateral condyle of the left femur, which was also confirmed by magnetic resonance imaging. Surgical resection of the tumor normalized the serum phosphorus and 1,25-dihydroxyvitamin D3 levels within 5 to 10 days, and FGF23 declined to normal levels within 24 hours. Histologic analysis supported the diagnosis of a soft-tissue giant cell tumor.
CONCLUSION: Our study case demonstrates the diagnostic complexity and difficulties in localizing a small tumor in a patient with TIO. Venous sampling for FGF23 may be helpful in tumor localization in sporadic cases of hypophosphatemic osteomalacia, especially when noninvasive diagnostic techniques prove insufficient.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18463045     DOI: 10.4158/EP.14.3.362

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  11 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

Review 2.  Disorders of phosphate homeostasis and tissue mineralisation.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Endocr Dev       Date:  2009-06-03

3.  Tumor-induced osteomalacia.

Authors:  Emily G Farrow; Kenneth E White
Journal:  Expert Rev Endocrinol Metab       Date:  2009-09-01

Review 4.  FGF23 and syndromes of abnormal renal phosphate handling.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

5.  Approach to the hypophosphatemic patient.

Authors:  Erik A Imel; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2012-03       Impact factor: 5.958

6.  Using (18)F-FDG PET/CT to Detect an Occult Mesenchymal Tumor Causing Oncogenic Osteomalacia.

Authors:  Hyo Jung Seo; Yun Jung Choi; Hyun Jeong Kim; Yong Hyu Jeong; Arthur Cho; Jae Hoon Lee; Mijin Yun; Jong Doo Lee; Won Jun Kang
Journal:  Nucl Med Mol Imaging       Date:  2011-07-14

Review 7.  FGF23 and Associated Disorders of Phosphate Wasting.

Authors:  Anisha Gohil; Erik A Imel
Journal:  Pediatr Endocrinol Rev       Date:  2019-09

8.  Selective venous catheterization for the localization of phosphaturic mesenchymal tumors.

Authors:  Panagiota Andreopoulou; Claudia E Dumitrescu; Marilyn H Kelly; Beth A Brillante; Carolee M Cutler Peck; Felasfa M Wodajo; Richard Chang; Michael T Collins
Journal:  J Bone Miner Res       Date:  2011-06       Impact factor: 6.741

9.  Tumor-induced osteomalacia with normal systemic fibroblast growth factor-23 level.

Authors:  Ambika Amblee; Juanito Uy; Carmencita Senseng; Peter Hart
Journal:  Clin Kidney J       Date:  2014-02-25

Review 10.  Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia.

Authors:  Seiji Fukumoto
Journal:  Endocrinol Metab (Seoul)       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.